Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA:600196)
China · Delayed Price · Currency is CNY 22.36
-0.51 (-2.23%)
Aug 31, 2026, 3:00 PM CST
SHA:600196 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 55,654 | 65,095 | 59,749 | 61,592 | 86,922 | 113,862 | |
Market Cap Growth | -21.05% | 8.95% | -2.99% | -29.14% | -23.66% | -9.48% |
Enterprise Value | 93,389 | 101,098 | 90,784 | 89,228 | 110,109 | 134,998 |
Last Close Price | 22.87 | 26.03 | 24.14 | 24.04 | 33.37 | 45.74 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.87 | 19.31 | 21.57 | 25.82 | 23.30 | 24.08 |
Forward PE | 22.87 | 34.77 | 21.15 | 21.49 | 19.36 | 20.43 |
PS Ratio | 1.31 | 1.56 | 1.46 | 1.49 | 1.98 | 2.92 |
PB Ratio | 0.88 | 1.05 | 1.00 | 1.09 | 1.61 | 2.35 |
P/TBV Ratio | 2.36 | 2.72 | 2.73 | 2.89 | 3.99 | 5.83 |
P/FCF Ratio | 79.53 | 85.12 | 894.58 | - | - | - |
P/OCF Ratio | 10.11 | 12.49 | 13.35 | 18.04 | 20.61 | 28.92 |
PEG Ratio | - | 1.02 | 1.02 | 1.02 | 1.02 | 1.02 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.19 | 2.43 | 2.21 | 2.15 | 2.51 | 3.46 |
EV/EBITDA Ratio | 14.81 | 17.18 | 16.34 | 22.98 | 19.87 | 32.27 |
EV/EBIT Ratio | 34.15 | 36.23 | 30.53 | 75.34 | 32.19 | 53.22 |
EV/FCF Ratio | 133.46 | 132.19 | 1359.25 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.62 | 0.59 | 0.60 | 0.62 | 0.56 | 0.53 |
Debt / EBITDA Ratio | 6.20 | 5.83 | 6.03 | 8.44 | 5.25 | 5.86 |
Debt / FCF Ratio | 55.89 | 47.63 | 539.31 | - | - | - |
Net Debt / Equity Ratio | 0.36 | 0.34 | 0.33 | 0.34 | 0.24 | 0.23 |
Net Debt / EBITDA Ratio | 3.91 | 3.58 | 3.58 | 5.01 | 2.35 | 2.60 |
Net Debt / FCF Ratio | 32.96 | 27.55 | 297.96 | -10.12 | -7.79 | -10.53 |
Asset Turnover | 0.35 | 0.35 | 0.36 | 0.38 | 0.44 | 0.44 |
Inventory Turnover | 3.31 | 3.09 | 2.90 | 3.01 | 3.77 | 3.82 |
Quick Ratio | 0.70 | 0.72 | 0.68 | 0.73 | 0.78 | 0.75 |
Current Ratio | 0.90 | 0.93 | 0.92 | 1.00 | 1.06 | 1.04 |
Return on Equity (ROE) | 6.95% | 6.98% | 6.03% | 5.23% | 7.70% | 10.55% |
Return on Assets (ROA) | 1.40% | 1.47% | 1.61% | 0.67% | 2.13% | 1.79% |
Return on Invested Capital (ROIC) | 2.71% | 2.85% | 3.21% | 1.47% | 4.67% | 3.56% |
Return on Capital Employed (ROCE) | 3.10% | 3.30% | 3.70% | 1.50% | 4.60% | 4.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.09% | 5.18% | 4.64% | 3.87% | 4.29% | 4.15% |
FCF Yield | 1.26% | 1.18% | 0.11% | -3.12% | -1.92% | -0.91% |
Dividend Yield | 1.65% | 1.50% | 1.33% | 1.12% | 1.26% | 1.22% |
Payout Ratio | 58.96% | 66.18% | 86.45% | 102.89% | 63.64% | 40.48% |
Buyback Yield / Dilution | 1.05% | 0.90% | -0.02% | -2.40% | -1.74% | - |
Total Shareholder Return | 2.70% | 2.40% | 1.31% | -1.27% | -0.48% | 1.22% |